#Italy #Milan #pharmaceuticals #Cambrex #R&D Center

Celebrating 80 Years of Innovation: Cambrex Milan's New R&D Center

Cambrex, a worldwide leader in contract development and manufacturing organizations (CDMO), recently announced significant news that marks a major milestone in its history. The company has commenced construction on a new research and development (R&D) facility in Milan, Italy, as part of its 80th-anniversary celebrations. This substantial investment, amounting to $30 million, will greatly enhance Cambrex's capabilities in analytical development and process R&D, reinforcing its commitment to supporting the advancement of complex small molecules in the pharmaceutical industry.

The new R&D facility is expected to be completed by the second half of 2027, a significant addition designed to accommodate future growth and the increasing demand for CDMO services. To further bolster its growth strategies, Cambrex has also acquired adjacent land, ensuring ample space for expansion and innovation as the company continues to evolve in response to market needs.

Cambrex Profarmico Milano has a longstanding reputation for excellence, supporting the development and manufacturing of pharmaceutical products for a diverse global clientele. To commemorate this milestone, the team in Milan gathered recently for a celebration, reflecting on the scientific achievements and dedication demonstrated over the past eight decades toward the enhancement of human health.

Claudio Russolo, Chief Operating Officer of Cambrex, underscored the significance of this initiative, stating, "The groundbreaking of our new facility is a testament to the enduring legacy and expertise of our Milan team. For 80 years, this site has been a cornerstone of pharmaceutical manufacturing in Europe. With this expansion, we are investing not only in advanced technologies and capabilities but also in the future of our workforce and partners."

This new development signifies a continuation of Cambrex's dedication to scientific excellence and manufacturing prowess, as the company positions itself for the next phase of growth. By expanding the R&D capabilities in Milan, Cambrex strengthens its ability to tackle the increasing complexities of modern therapies utilizing small molecules.

About Cambrex

Cambrex is a prominent global organization focused on contract development and manufacturing (CDMO). It offers a wide array of development and manufacturing services for active pharmaceutical ingredients (APIs) and provides comprehensive analytical services throughout the entire drug lifecycle.

With over 45 years of experience and a workforce of 2,000 experts serving clients globally—from North America to Europe—Cambrex boasts a rich portfolio of specialized technologies and capabilities in active pharmaceutical ingredients. These include continuous flow, controlled substances, peptide synthesis, solid-state chemistry, biocatalysis, material characterization, complex synthetic compounds, and high-potency APIs.

As Cambrex moves forward, it remains committed to innovation and excellence, ready to meet the challenges and demands of an ever-evolving pharmaceutical landscape.